ONCOLOGY DRUG DEVELOPMENT SOLUTIONSSucceed in a Competitive Drug Development Landscape With an Experienced and Trusted PartnerOncology has become one of the most research-intensive therapeutic areas, and the oncology treatment paradigm has recently shifted to a more patient-centric approach. Personalized medicine and targeted therapies continue to receive growing attention, and the number of trials is on the rise. Drug developers now face many challenges in such a competitive environment, including locating and recruiting target patients, validating biomarkers and establishing a product niche.

ONCOLOGY DRUG DEVELOPMENT PAIN POINTS► Increasing numbers of trials mean increased

competition for eligible patients

► Increased focus on personalized therapies requires parallel validation of biomarkers and companion diagnostics (CDx)

►As the field advances, trial protocols are becoming more complicated and demand greater flexibility

► A rapidly changing and crowded marketplace makes it difficult to establish a company’s optimum position

Covance Brings Focus and Proven Experience to Oncology Development

731 studies*

21,132 sites in 74 countries

112,646 patients

50% of Covance experience is in Oncology

*Five year experience 2013-2017

2,000 Clinical Operations 1,280 Project Leaders 5,000+ total staff with oncology experience

>100 Global locations

PhaseI II III

225 Studies1653 Sites13,093 Pts

156 Studies 4165 Sites15,336 Pts

161 Studies12,167 Sites61,377 Pts

CREATING COLLATERAL

Learn more about our drug development solutions at www.covance.comCovance Inc., headquartered in Princeton, NJ, USA is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is registered trademark and themarketing name for Covance Inc. and its subsidiaries around the world.

The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440 Europe / Africa +00.800.2682.2682 +44.1423.500888 Asia Pacific +800.6568.3000 +65.6.5686588

© Copyright 2018 Covance Inc. SSCDS082-0518

ONCOLOGY DRUG DEVELOPMENT SOLUTIONSEnd-to-End Clinical Development Solutions for Overcoming Oncology Trial ChallengesCovance is partnered with Integrated Oncology and OmniSeq, both LabCorp Specialty Testing Groups specializing in personalized medicine and innovative molecular testing assays.

COMMUNICATING PRODUCT VALUE AND ESTABLISHING A NICHE►Design the optimal strategy to take your molecule from discovery to commercialization

►Generate real-world data and communicate this to relevant stakeholders via Covance Market Access

►Covance has worked on more than 90% of the novel oncology drugs approved by the FDA over the last five years.

OPTIMIZING TRIAL DESIGN AND CONTROLLING PROTOCOL COMPLEXITY ►Refine eligibility criteria and other protocol parameters prior to finalization by pressure testing

decisions using Xcellerate® Trial Design

►Early Phase Development Solutions team align nonclinical plan with clinical endpoints to expeditethe path to first-in-human studies

►Expertise in adaptive trial design (including biomarker-guided trial design)

►Covance has successfully conducted over 730 oncology trials (including more than 110 IO trials) since 2013.

VALIDATING BIOMARKERS AND COMPANION DIAGNOSTIC ASSAYS►Expertise in biomarker validation and assay feasibility, development and production

►Collectively, LabCorp, Covance Central Laboratories and Covance Translational Biomarker Solutions offer >3,600 tests across 50 disciplines

►Collaborated with over 40 clients on more than 165 CDx projects in 2017

►Covance and LabCorp have supported >65% of all FDA-approved CDx assays, including recent approvals for HER2, KRAS, EGFR, BRAF and ALK

►Covance Central Laboratories has supported >150 IO trials in the last five years.

FINDING AND RECRUITING PATIENTS USING PROPRIETARY DATA►Opt-in patient initiative currently has 150,000 patients

►Clinical trial knowledgebase houses >50% of all global trial data used to locate target patient populations

►Target sites with experience and high recruitment rates using Covance Xcellerate® Trial Design

►Through Covance Central Laboratories, we have access to >1,900 global studies, >320k patients and >50k sites in 85 countries in the last five years

►Access to over 13 billion lab test results and 142 million de-identified patients through LabCorp in the US